Provided by Tiger Trade Technology Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

341.75
-22.2700-6.12%
Volume:190.88K
Turnover:65.86M
Market Cap:38.96B
PE:61.14
High:353.41
Open:351.94
Low:340.45
Close:364.02
52wk High:385.22
52wk Low:253.95
Shares:114.00M
Float Shares:80.95M
Volume Ratio:1.49
T/O Rate:0.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.59
EPS(LYR):2.47
ROE:14.66%
ROA:7.46%
PB:7.53
PE(LYR):138.36

Loading ...

New Combo Trial in Esophageal Cancer: What LBL-007’s Phase 2 Update Means for ONC Investors

TIPRANKS
·
May 29

Hong Kong Stock Connect Biotech Sector Extends Over 8-Month Slump, Key ETF Hits Record Low

Deep News
·
May 28

BeOne Medicines’ combination shows improved survival in adenocarcinoma

TIPRANKS
·
May 28

Hang Seng Index Quarterly Review Boosts Industrial and Healthcare Sector Coverage; Six Stocks May Enter Southbound Trading

Stock News
·
May 25

Hang Seng Index Quarterly Review Results Announced: New Additions Include J&T Express, BeiGene, and CHALCO

Deep News
·
May 22

Zhipu and MiniMax Poised for Inclusion in Hang Seng Tech Index

Deep News
·
May 22

BeOne Medicines (ONC) Gets a Buy from J.P. Morgan

TIPRANKS
·
May 20

BEIGENE Shares Rise Nearly 3% on FDA Accelerated Approval for Sotoklara and Strong Q1 Earnings Beat

Stock News
·
May 20

Major Financial Institutions Bullish on BEIGENE, Q1 Performance Confirms Long-Term Investment Value

Stock News
·
May 19

Beone Medicines : Leerink Partners Raises Target Price to $367 From $364

THOMSON REUTERS
·
May 15

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR)

TIPRANKS
·
May 14

BEIGENE's BEQALZI™ Secures FDA Accelerated Approval as First and Only BCL2 Inhibitor for Relapsed/Refractory Mantle Cell Lymphoma in the U.S.

Stock News
·
May 14

BeOne Medicines’ Beqalzi granted accelerated approval by FDA

TIPRANKS
·
May 14

BeOne Medicines Gets FDA Accelerated Approval for Lymphoma Drug

Dow Jones
·
May 14

BEIGENE Announces Grant of Restricted Stock Units

Stock News
·
May 13

BEIGENE Reports Q1 Profit Turnaround with 1.6 Billion Yuan Net Income

Stock News
·
May 11

CICC Maintains Outperform Rating on BEIGENE with HK$250 Target Price

Stock News
·
May 08

Leadership Reshuffle Sweeps Pharmaceutical Sector: Hengrui, Fosun, AstraZeneca, Pfizer Among Key Players

Deep News
·
May 07

BeOne Medicines Shares Surge After Robust First-Quarter

Dow Jones
·
May 07

BEIGENE's Q1 Net Profit Soars 399% Sequentially, Shares Jump 7% Post-Earnings

Deep News
·
May 07